Figure 1
Figure 1. Pre-HSCT serum levels of Ang-2 lack association with disease, response to prior treatment, and cytogenetic risk groups. (A) Pre-HSCT serum levels of Ang-2 are elevated in patients compared with healthy controls. Levels of Ang-2 in healthy controls (n = 20; median, 0.87 ng/mL; range, 0.27-4.51 ng/mL) were significantly lower than pre-HSCT Ang-2 levels in patients with myeloid malignancies (median, 2.21 ng/mL; range, 0.18-48.84 ng/mL; P < .001). Ang-2 levels did not differ between patients with de novo AML (n = 39; median, 2.34 ng/mL; range, 0.36-4.03 ng/mL), secondary AML (n = 40; median, 2.13 ng/mL; range, 1.18-48.84 ng/mL), or MDS (n = 11; median, 2.57 ng/mL; range, 0.53-5.17 ng/mL), respectively (P = .579). Horizontal bars indicate median values. (B) Pre-HSCT serum levels of Ang-2 are not associated with response to prior treatment. Levels of Ang-2 in healthy controls (n = 20; median, 0.87 ng/mL; range, 0.27-4.51 ng/mL) were significantly lower than pre-HSCT Ang-2 levels in patients who achieved first or second complete remission (CR, n = 17: median, 2.35 ng/mL; range, 0.81-4.19 ng/mL), patients who were untreated (n = 16: median, 2.29 ng/mL; range, 0.53-5.17 ng/mL), patients with primary induction failure (PIF, n = 28: median, 2.11 ng/mL; range, 0.18-6.56 ng/mL), and patients who had a relapse (n = 29: median, 2.21 ng/mL; range, 0.46-48.84 ng/mL). Ang-2 levels did not differ between patients with different disease stages at transplantation (P = .798). Horizontal bars indicate median values. (C) Pre-HSCT Ang-2 levels are not different according to distinct cytogenetic risk groups. Pre-HSCT Ang-2 levels were not different between patients with good or standard risk cytogenetics compared with high risk (according to Southwest Oncology Group/Eastern Cooperative Oncology Group Study5 criteria and FLT3 mutations63,64) good risk/standard risk (n = 38: median, 2.10 ng/mL; range, 0.18-46.42 ng/mL) and high risk (n = 49: median, 2.35 ng/mL; range, 0.53-48.84 ng/mL; P = .221). Three patients with cytogenetics of unknown significance could not be considered. Horizontal bars indicate median values.

Pre-HSCT serum levels of Ang-2 lack association with disease, response to prior treatment, and cytogenetic risk groups. (A) Pre-HSCT serum levels of Ang-2 are elevated in patients compared with healthy controls. Levels of Ang-2 in healthy controls (n = 20; median, 0.87 ng/mL; range, 0.27-4.51 ng/mL) were significantly lower than pre-HSCT Ang-2 levels in patients with myeloid malignancies (median, 2.21 ng/mL; range, 0.18-48.84 ng/mL; P < .001). Ang-2 levels did not differ between patients with de novo AML (n = 39; median, 2.34 ng/mL; range, 0.36-4.03 ng/mL), secondary AML (n = 40; median, 2.13 ng/mL; range, 1.18-48.84 ng/mL), or MDS (n = 11; median, 2.57 ng/mL; range, 0.53-5.17 ng/mL), respectively (P = .579). Horizontal bars indicate median values. (B) Pre-HSCT serum levels of Ang-2 are not associated with response to prior treatment. Levels of Ang-2 in healthy controls (n = 20; median, 0.87 ng/mL; range, 0.27-4.51 ng/mL) were significantly lower than pre-HSCT Ang-2 levels in patients who achieved first or second complete remission (CR, n = 17: median, 2.35 ng/mL; range, 0.81-4.19 ng/mL), patients who were untreated (n = 16: median, 2.29 ng/mL; range, 0.53-5.17 ng/mL), patients with primary induction failure (PIF, n = 28: median, 2.11 ng/mL; range, 0.18-6.56 ng/mL), and patients who had a relapse (n = 29: median, 2.21 ng/mL; range, 0.46-48.84 ng/mL). Ang-2 levels did not differ between patients with different disease stages at transplantation (P = .798). Horizontal bars indicate median values. (C) Pre-HSCT Ang-2 levels are not different according to distinct cytogenetic risk groups. Pre-HSCT Ang-2 levels were not different between patients with good or standard risk cytogenetics compared with high risk (according to Southwest Oncology Group/Eastern Cooperative Oncology Group Study criteria and FLT3 mutations63,64 ) good risk/standard risk (n = 38: median, 2.10 ng/mL; range, 0.18-46.42 ng/mL) and high risk (n = 49: median, 2.35 ng/mL; range, 0.53-48.84 ng/mL; P = .221). Three patients with cytogenetics of unknown significance could not be considered. Horizontal bars indicate median values.

Close Modal

or Create an Account

Close Modal
Close Modal